PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2092754
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2092754
Oral Biologics & Biosimilars Market size was valued at US$ 8,790.3 Million in 2025, expanding at a CAGR of 15.8% from 2026 to 2033.
The oral biologics & biosimilars market consists of biologics, biosimilars, and sophisticated biologics, which are used in oral delivery through drug delivery technologies that ensure protection against degradation in the gastrointestinal system and facilitate absorption. Unlike traditional injectable biologics, oral biologics have been formulated to increase ease of use and treatment adherence and for better disease management over a period of time.
The industry encompasses various categories such as oral proteins, peptides, monoclonal antibodies, hormones, and other sophisticated biologics, which have been formulated for the treatment of metabolic disorders, autoimmune disorders, gastrointestinal diseases, oncology, respiratory diseases, and neurological diseases. The market growth has been boosted by continuous advancements in oral delivery systems, enteric coatings, permeation enhancers, and capsule delivery systems, which help in efficient delivery and absorption of large molecules. Collaborations between pharmaceutical firms and drug delivery technology providers, increased biosimilar development, and expansion of biologics pipeline are contributing to growth.
Oral Biologics & Biosimilars Market- Market Dynamics
Advancements in oral biologic drug delivery technologies
Rising innovation in the technology of drug delivery via oral route is one of the primary drivers driving the market for oral biologics & biosimilars forward. Pharma companies are making efforts to invent capsule-based delivery mechanisms, permeation enhancing techniques, and formulations for the protection of protein, peptide, and monoclonal antibody drugs from destruction within the digestive tract. These developments have the potential to make life more convenient for patients and ensure improved treatment by reducing the requirement for administration through the injection route. An example of this is the collaboration of Rani Therapeutics with Chugai Pharmaceutical in October 2025 for the development of an oral antibody drug with the help of RaniPill(R) technology. The contract is worth up to USD 1.085 billion.
The Global Oral Biologics & Biosimilars Market is segmented on the basis of Product Type, Application, Distribution, and Region.
In terms of product type, the worldwide Oral Biologics & Biosimilars industry is estimated to be dominated by Proteins & Peptides segment. Growth is supported by the rising adoption of these drugs in the treatment of diabetes, obesity, and other metabolic diseases along with constant improvement in the methods of oral drug delivery. In addition, the successful commercialization of oral peptide drugs has instilled confidence in this category, and has paved the way for further pipeline expansion. As per Novo Nordisk's annual report of 2025, total revenue from Rybelsus(R) (oral semaglutide) in 2025 was worth DKK 23.7 billion, indicating high acceptance of peptide-based oral drugs among physicians and patients. Monoclonal Antibodies category is expected to be the future segment in oral biologics & biosimilars market as oral delivery technology of these drugs moves closer towards commercialization.
Oral Biologics & Biosimilars Market- Geographical Insights
North America region is accounted for the maximum revenue share in this market. Robust pipelines for biologics, high incidence of chronic diseases, and regulatory initiatives focused on enhancing biosimilar availability has supported the regional growth. Moreover, the U.S. FDA is actively involved in the approval of biosimilars, with proposals to reduce the need for switching studies for interchangeable biosimilars. Europe too will remain significant in the context of oral biologics & biosimilars, because the EMA centrally assesses majority of the biosimilars' application along with providing scientific advice on biosimilars development. Asia Pacific will see steady growth driven by growing biologics production, government biosimilar guidelines, and increased access to advanced treatments in countries like India, China, Japan, and South Korea.
The global market is driven by strategic alliances among pharma companies and oral drug delivery platform developers. Top competitors such as Novo Nordisk, Eli Lilly and Company, Novartis, Sanofi, AstraZeneca, and Rani Therapeutics are making significant investments in novel oral delivery systems, peptide drugs, and new generation biologics to increase their product portfolio offerings.
Major players are increasingly interested in enhancing the bioavailability, gastrointestinal stability, and patient compliance of their products without being heavily dependent on injectable forms. Some of the important strategies used by these players include licensing and technology partnerships along with pipeline expansion initiatives.